Background: In the recent years, immunotherapeutics and specifically immunecheckpoints inhibitors have marked a significant shift in the diagnostic and therapeutic algorithm of Non-Small Cell Lung Cancer (NSCLC), allowing us to use immunotherapeutics alone or combined with chemotherapy for a great subset of patients. However, new interesting approaches are being presently investigated, markedly immunotherapy combinations, that is, the use of two or more immunotherapeutics combined.
Methods: In particular, the combination of anti-PD-1 nivolumab and anti-CTLA-4 ipilimumab has already provided groundbreaking positive results in the advanced NSCLC and other combinations are currently under investigation.
Results: Therefore, this paper aims to provide a comprehensive state-of-the-art review about immunotherapy combination, along with suggestions about future directions. A comprehensive literature search was carried out to identify eligible studies from MEDLINE/PubMed and ClinicalTrials.gov.
Conclusion: Nivolumab plus ipilimumab represent the most promising immunotherapy combination for the treatment of advanced NSCLC patients; safety, tolerability and efficacy of new immunotherapeutics (in monotherapy and in immunotherapy combinations) must be further assessed in future studies.
[http://dx.doi.org/10.1186/s40425-018-0349-3] [PMID: 29769148]
[http://dx.doi.org/10.1007/s00262-017-2039-2] [PMID: 28707078]
[http://dx.doi.org/10.1111/j.1365-2567.2010.03398.x] [PMID: 21214544]
[http://dx.doi.org/10.1111/j.1365-2567.2011.03415.x] [PMID: 21342183]
[http://dx.doi.org/10.2147/DDDT.S163304] [PMID: 29731605]
[http://dx.doi.org/10.1111/j.1600-065X.2009.00765.x] [PMID: 19426223]
[http://dx.doi.org/10.1111/j.1600-065X.2009.00766.x] [PMID: 19426222]
[http://dx.doi.org/10.1053/j.seminoncol.2010.09.013] [PMID: 21074068]
[http://dx.doi.org/10.20892/j.issn.2095-3941.2016.0015] [PMID: 27458526]
[http://dx.doi.org/10.1016/j.cllc.2016.03.003] [PMID: 27265743]
[http://dx.doi.org/10.1016/S1470-2045(16)30624-6] [PMID: 27932067]